| Literature DB >> 34874534 |
Simon Leigh1,2, Max E Noble3, Frances E Pearson3, James Iremonger3, David T Williams3.
Abstract
BACKGROUND: Engaging influential stakeholders in meaningful exchange is essential for pharmaceutical companies aiming to improve care. At a time where opportunities for face-to-face engagement are limited, the ability to interact, learn and generate actionable insights through digital channels such as Twitter, is of considerable value. AIM: The aim of this study was to evaluate digital engagement among global diabetes mellitus researchers.Entities:
Mesh:
Year: 2021 PMID: 34874534 PMCID: PMC8650740 DOI: 10.1007/s40290-021-00408-6
Source DB: PubMed Journal: Pharmaceut Med ISSN: 1178-2595
Fig. 1Schematic of the study design
Characteristics of the study cohort
| Mean | SD | Minimum | Maximum | |
|---|---|---|---|---|
| Length of Twitter account activity (months) | 84.5 | 38.1 | 0.3 | 164 |
| Total diabetes-related tweets | 41.1 | 189.8 | 1 | 5876 |
| Retweets | 23.3 | 82.4 | 0 | 1533 |
| Original posts | 14.0 | 79.5 | 0 | 2457 |
| Comments and replies | 6.8 | 63.5 | 0 | 2858 |
| Number of times author has been retweeted by others | 4.6 | 51.4 | 0 | 1592 |
| Number of times author has been replied to by others | 1.6 | 16.1 | 0 | 626 |
| Total number of Twitter followers | 1931 | 10,331 | 0 | 359,752 |
| Total scientific publications | 13 | 27 | 2 | 469 |
| Publications/month | 1 | 1 | 0.1 | 20 |
| First/last authorships | 5 | 11 | 0 | 192 |
| Diabetes co-authors | 157 | 686 | 0 | 6271 |
SD standard deviation
Factors associated with the likelihood of publishing original Twitter content
| Exp (b) | Std error | Z score | 95% CI (low) | 95% CI (high) | ||
|---|---|---|---|---|---|---|
| Age of Twitter account (months) | 0.994 | 0.001 | −4.420 | 0.000 | 0.992 | 0.997 |
| Followers | ||||||
| 251–500 | 2.012 | 0.347 | 4.060 | 0.000 | 1.435 | 2.820 |
| 501–2000 | 4.187 | 0.616 | 9.730 | 0.000 | 3.137 | 5.587 |
| 2001–5000 | 6.894 | 1.696 | 7.850 | 0.000 | 4.257 | 11.166 |
| 5001–10,000 | 14.130 | 4.079 | 9.170 | 0.000 | 8.024 | 24.882 |
| 10,000+ | 12.495 | 8.299 | 3.800 | 0.000 | 3.399 | 45.926 |
| Publication impact factor | 1.024 | 0.007 | 3.280 | 0.001 | 1.010 | 1.039 |
| Total publications | 1.010 | 0.007 | 1.410 | 0.159 | 0.996 | 1.024 |
| Publications/month | ||||||
| 1–3 | 0.778 | 0.190 | − 1.030 | 0.302 | 0.482 | 1.254 |
| 4–6 | 0.420 | 0.290 | − 1.260 | 0.209 | 0.109 | 1.626 |
| 7+ | 0.450 | 0.688 | − 0.520 | 0.601 | 0.022 | 8.998 |
| First/last authorships per month | ||||||
| 1–2 | 1.490 | 0.404 | 1.470 | 0.141 | 0.877 | 2.534 |
| 2–3 | 3.379 | 2.614 | 1.570 | 0.116 | 0.742 | 15.388 |
| 4+ | 0.789 | 0.642 | −0.290 | 0.771 | 0.160 | 3.889 |
| Publication co-authors | ||||||
| 50–100 | 0.520 | 0.090 | − 3.760 | 0.000 | 0.370 | 0.731 |
| 101–200 | 0.577 | 0.163 | − 1.950 | 0.049 | 0.332 | 1.003 |
| 201+ | 0.477 | 0.103 | − 3.430 | 0.001 | 0.313 | 0.728 |
CI confidence interval, Exp (b) exponentiated GLM co-efficient, Std standard
Factors associated with the likelihood of being retweeted by others
| Exp (b) | Std error | Z score | 95% CI (low) | 95% CI (high) | ||
|---|---|---|---|---|---|---|
| Age of Twitter account (months) | 1.000 | 0.002 | 0.230 | 0.817 | 0.997 | 1.004 |
| Followers | ||||||
| 250–500 | 4.197 | 1.215 | 4.950 | 0.000 | 2.380 | 7.403 |
| 501–2000 | 6.075 | 1.043 | 10.510 | 0.000 | 4.339 | 8.505 |
| 2001–5000 | 16.250 | 4.087 | 11.090 | 0.000 | 9.926 | 26.602 |
| 5001–10,000 | 36.876 | 12.416 | 10.710 | 0.000 | 19.062 | 71.340 |
| Followers (10,000+) | 34.987 | 26.087 | 4.770 | 0.000 | 8.114 | 150.860 |
| Publication impact factor | 1.048 | 0.009 | 5.540 | 0.000 | 1.031 | 1.065 |
| Total publications | 1.004 | 0.006 | 0.730 | 0.468 | 0.993 | 1.015 |
| Publications/month | ||||||
| 1–3 | 0.780 | 0.243 | − 0.800 | 0.425 | 0.424 | 1.436 |
| 4–6 | 0.129 | 0.075 | − 3.52 | 0.000 | 0.041 | 0.403 |
| 7+ | 0.174 | 0.209 | − 1.46 | 0.145 | 0.016 | 1.829 |
| First/last authorships per month | ||||||
| 1–2 | 0.780 | 0.243 | − 0.800 | 0.425 | 0.424 | 1.436 |
| 2–3 | 0.129 | 0.075 | − 3.520 | 0.000 | 0.041 | 0.403 |
| 4+ | 0.174 | 0.209 | − 1.460 | 0.145 | 0.017 | 1.829 |
| Publication co-authors | ||||||
| 50–100 | 0.567 | 0.152 | − 2.120 | 0.034 | 0.335 | 0.958 |
| 101–200 | 0.861 | 0.320 | − 0.400 | 0.687 | 0.416 | 1.783 |
| 201+ | 1.451 | 0.522 | 1.030 | 0.301 | 0.717 | 2.937 |
CI confidence interval, Exp (b) exponentiated GLM co-efficient, Std standard error
Factors associated with the likelihood of being replied to or commented on by others
| Exp (b) | Std error | Z score | 95% CI (low) | 95% CI (high) | ||
|---|---|---|---|---|---|---|
| Age of Twitter account (months) | 1.004 | 0.002 | 1.980 | 0.047 | 1.000 | 1.009 |
| Followers | ||||||
| 250–500 | 6.610 | 2.438 | 5.120 | 0.000 | 3.208 | 13.619 |
| 501–2000 | 9.252 | 2.383 | 8.640 | 0.000 | 5.585 | 15.328 |
| 2001–5000 | 20.607 | 5.446 | 11.450 | 0.000 | 12.276 | 34.592 |
| 5001–10,000 | 90.426 | 31.938 | 12.750 | 0.000 | 45.254 | 180.688 |
| 10,000+ | 22.994 | 14.257 | 5.060 | 0.000 | 6.821 | 77.512 |
| Publication impact factor | 1.045 | 0.011 | 4.340 | 0.000 | 1.025 | 1.066 |
| Total publications | 1.000 | 0.006 | 0.070 | 0.947 | 0.989 | 1.012 |
| Publications/month | ||||||
| 1–3 | 0.302 | 0.117 | − 3.100 | 0.002 | 0.142 | 0.643 |
| 4–6 | 0.082 | 0.067 | − 3.040 | 0.002 | 0.016 | 0.410 |
| 7+ | 0.090 | 0.137 | − 1.590 | 0.112 | 0.005 | 1.759 |
| First/last authorships per month | ||||||
| 1–2 | 2.600 | 1.048 | 2.370 | 0.018 | 1.181 | 5.727 |
| 2–3 | 2.069 | 1.616 | 0.930 | 0.352 | 0.448 | 9.561 |
| 4+ | 1.113 | 1.063 | 0.110 | 0.911 | 0.171 | 7.235 |
| Publication co-authors | ||||||
| 50–100 | 0.846 | 0.242 | − 0.580 | 0.559 | 0.483 | 1.483 |
| 101–200 | 1.191 | 0.485 | 0.430 | 0.668 | 0.536 | 2.646 |
| 201+ | 1.102 | 0.545 | 0.200 | 0.844 | 0.419 | 2.903 |
CI confidence interval, Exp (b) exponentiated GLM co-efficient, Std standard
Factors associated with the likelihood of replying to or commenting on others’ content
| Exp (b) | Std error | Z score | 95% CI (low) | 95% CI (high) | |||
|---|---|---|---|---|---|---|---|
| Age of Twitter account (months) | 1.004 | 0.002 | 2.470 | 0.013 | 1.001 | 1.007 | |
| Followers | |||||||
| 250–500 | 1.532 | 0.558 | 1.170 | 0.242 | 0.750 | 3.127 | |
| 501–2000 | 3.732 | 1.371 | 3.580 | 0.000 | 1.816 | 7.668 | |
| 2001–5000 | 7.190 | 2.656 | 5.340 | 0.000 | 3.486 | 14.832 | |
| 5001–10,000 | 28.349 | 12.315 | 7.700 | 0.000 | 12.099 | 66.423 | |
| 10,000+ | 17.208 | 13.329 | 3.670 | 0.000 | 3.771 | 78.528 | |
| Publication impact factor | 1.011 | 0.012 | 0.940 | 0.349 | 0.988 | 1.034 | |
| Total publications | 1.011 | 0.008 | 1.380 | 0.166 | 0.996 | 1.026 | |
| Publications/month | |||||||
| 1–3 | 0.422 | 0.150 | − 2.430 | 0.015 | 0.211 | 0.846 | |
| 4–6 | 0.133 | 0.105 | − 2.550 | 0.011 | 0.028 | 0.625 | |
| 7+ | 0.096 | 0.134 | − 1.680 | 0.050 | 0.006 | 1.475 | |
| First/last authorships per month | |||||||
| 1–2 | 2.247 | 0.846 | 2.150 | 0.032 | 1.074 | 4.702 | |
| 2–3 | 1.075 | 0.545 | 0.140 | 0.887 | 0.397 | 2.906 | |
| 4+ | 0.486 | 0.448 | − 0.780 | 0.434 | 0.080 | 2.959 | |
| Publication co-authors | |||||||
| 50–100 | 0.681 | 0.168 | − 1.550 | 0.120 | 0.419 | 1.106 | |
| 101–200 | 0.862 | 0.266 | − 0.480 | 0.629 | 0.470 | 1.578 | |
| 201+ | 0.827 | 0.312 | − 0.500 | 0.615 | 0.394 | 1.734 | |
CI confidence interval, Exp (b) exponentiated GLM co-efficient, Std standard
Link between academic interests and Twitter interests
| Insulin tweets | Paediatric tweets | Type-1 tweets | Type-2 tweets | Outcomes tweets | Conference tweets | |
|---|---|---|---|---|---|---|
| Age of Twitter account (months) | 1.001 | 1.001 | 1.001 | 1.000 | 1.000 | 1.006 |
| Followers (250–500) | 0.962 | 1.526** | 1.086 | 1.832* | 1.481* | 0.970 |
| Followers (501–2000) | 2.322* | 2.249* | 1.800* | 3.209* | 3.342* | 2.168* |
| Followers (2001–5000) | 2.957* | 2.513* | 1.494 | 4.207* | 4.602* | 7.093* |
| Followers (5001–10,000) | 9.343* | 5.223* | 5.607* | 9.932* | 8.654* | 15.154* |
| Followers (10,000 +) | 4.149* | 2.443* | 1.338 | 1.955* | 1.810* | 1.181 |
| Publication Impact Factor | 1.009 | 1.025* | 1.036* | 1.029* | 1.021* | 1.035 |
| Total publications | 1.011 | 0.996 | 1.014 | 0.997 | 1.006 | 1.013 |
| Publications/month (1–3) | 0.522** | 0.664 | 0.312* | 0.527* | 0.535* | 0.583 |
| Publications/month (4–6) | 0.176* | 0.066* | 0.039* | 0.415 | 0.129* | 0.080 |
| Publications/month (7+) | 0.095 | 0.080 | 0.057 | 0.778 | 0.156 | 0.057 |
| First/last authorships per month (1–2) | 2.631* | 2.466* | 1.433 | 1.472 | 2.095* | 1.551 |
| First/last authorships per month (2–3) | 6.757* | 102.423* | 8.021* | 1.795 | 8.329* | 9.258 |
| First/last authorships per month (4+) | 1.110 | 21.867* | 0.357 | 1.326 | 1.335 | 0.372 |
| Publication co-authors (50–100) | 0.744 | 0.524* | 0.426* | 0.864 | 0.814 | 0.695c |
| Publication co-authors (101–200) | 0.952 | 1.104 | 1.062 | 1.377 | 1.502 | 0.863 |
| Publication co-authors (201 +) | 0.629 | 0.836 | 1.075 | 1.707 | 1.318 | 1.071 |
| Total T1DM publications | 1.028 | 0.868 | 1.253* | 0.950 | 1.050 | 0.881 |
| T1DM first/last authorships | 1.046 | 1.361 | 1.192 | 1.020 | 0.902 | 1.619* |
| Total T2DM publications | 1.102 | 1.079 | 0.998 | 1.044 | 0.886* | 0.945 |
| T2DM first/last authorships | 0.896 | 1.059 | 1.142 | 1.295* | 1.144 | 1.134 |
| Total paediatric publications | 0.989 | 1.796* | 0.881 | 0.995 | 0.990 | 0.942 |
| Paediatric first/last authorships | 0.616** | 0.641** | 0.802 | 0.577* | 0.562* | 0.611 |
| Total insulin publications | 1.192* | 1.009 | 0.947 | 1.207** | 0.971 | 1.334* |
| Insulin first/last authorships | 1.053 | 0.974 | 1.267 | 0.866 | 1.230 | 0.638 |
| Total outcomes publications | 0.823* | 0.916 | 0.912 | 0.902* | 1.142* | 1.006 |
| Outcomes first/last authorships | 1.059 | 0.888 | 0.825** | 0.870 | 0.889 | 0.867 |
*Denotes statistical significance (p < 0.05), ** denotes numerical significance (0.05 < p< 0.1)
T1DM type-1 diabetes mellitus,T2DM type-2 diabetes mellitus
| The dissemination of scientific information has seen a move towards the use of digital platforms such as Twitter to reach wider and more varied audiences. |
| As such, there is a growing need to analyse both social content as well as academic content from key opinion leaders (KOLs) for a rounded view of the field, as is required by pharmaceutical Medical Science Liaisons (MSLs). |
| ‘Digital opinion leaders’ (those most active and reaching the highest audiences on Twitter) were typically less well-established in the publishing sphere within their individual fields. They are critical to the scientific discourse and are important to consider alongside traditional ‘key opinion leaders’. |